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Background: Neuroinflammation has a definitive role in neurodegenerative 
diseases, such as Parkinson’s and Alzheimer’s disease. In addition to its pathoge-
nic ligands, toll-like receptors (TLRs) can be activated by damaged endogenous 
molecules that induce inflammatory signalling pathways such as high-mobility 
group box 1 protein (HMGB1). 
Materials and methods: Using an ex-vivo rat optic nerve (RON) model, we sought 
to determine the effects of lipopolysaccharides (LPS; TLR4 agonist), zymosan (TLR2 
agonist) or HMGB1 — with or without TLR2/4 antagonists, on the expression of 
glial fibrillary acidic protein (GFAP) and nuclear factor kappa B (NF-ҡβ) for signalling 
pathway and astrocyte reactivity, using double immunohistochemistry; as well as 
on the modulation of the neurotoxicity. HMGB1-treated RON had significantly 
higher expression and co-localisation of GFAP and NF-ҡβ as compared to the un-
treated control, which was a similar result to those treated with LPS and zymosan. 
Results: Moreover, the HMGB1-induced inflammation was blocked by TLR2/4 
antagonists (p = 0.05). However, the HMGB1-induced cell death was unblocked 
by TLR antagonists. Overall, HMGB1 endogenously mediates the signalling me-
chanisms of neuroinflammation through TLR2/4. 
Conclusions: Whereas, the neuronal death mechanism resulting from HMGB1 
could be caused by a different signalling pathway. Gaining an understanding of 
these mechanisms may help researchers discover new therapeutic targets for 
neurodegenerative diseases. (Folia Morphol 2018; 78, 1: 10–16)
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INTRODUCTION 
From series studies of the literatures, strong ev-
idence has been established regarding the contri-
bution of an innate immune system in regulating 
neurological functions, whether in health or disease 
[4, 18, 21, 22, 24]. This system recognises invading 
microorganisms using pattern-recognition receptors 
(PRRs) [28]. Toll-like receptors (TLRs) are the most 
commonly studied family of PRRs. TLR expression 
has been shown in various particles found inside 
the central nervous system, including microglia [20], 
astrocytes [7], oligodendrocytes [25], neurons and 
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neuronal progenitor cells [29]. These proteins induce 
the nuclear factor-kappa B (NF-ҡβ) signalling pathway 
[28]. Additionally, astrocytes and microglia induce 
MyD88 and TRIF, thereby creating NF-ҡβ signalling 
pathways throughout the TLR4-mediated pro-inflam-
matory environment [11]. 
Nuclear factor-kappa B is a transcription factor that 
is translocated into the nucleus and that triggers the 
transcription of several genes implicated in immune 
responses, such as the releasing of pro-inflammatory 
cytokines, e.g. tumour necrosis alpha and interleukin-6 
(Il-6) [5]. NF-ҡβ is a centre for regulating inflammation 
in all cellular types within mammal’s bodies, mediated 
by several stimulators, such as viruses, bacterial, matrix 
metalloproteinases, C-reactive protein, chemokines, 
cytokines and adhesion molecules [5]. Its stimulation 
plays a main role in immune responses and cell sur-
viving [5]. The NF-ҡβ is formed from five dissimilar 
subunits including NF-ҡβ1 (p50), RelA (p65), RelB, 
RelC, and NF-ҡβ2 (p52) [3]. The triggered NF-ҡβ sub-
units will gather to form the complexes of the homo- 
or hetero-dimerised transcription factor. According 
to the formed dimer, the cellular function proceeds 
despite neuronal inflammation or neurotoxicity or in 
the presence of neuronal defences [27]. 
When no infection exists, TLRs interact with host-de-
rived endogenous molecules and induce immune re-
sponses [2, 16]. These damage-associated molecular 
pattern molecules (DAMPs) include the high-mobility 
group box 1 protein (HMGB1) [31]. There is substantial 
evidence to support the theory that TLR stimulation 
by endogenous ligands can contribute to pathology 
of neurodegenerative diseases [9, 16]. For example, 
HMGB1 is an endogenous ligand of TLR4-induced 
stimulation of neuroinflammation that occurs after 
brain trauma [15]. HMGB1 is a DNA-binding nuclear 
protein that is widely distributed in all cells of the 
vertebrae. Extra-nuclear HMGB1 is produced from 
inflamed necrotic cells, such as macrophages, and it 
behaves like a pro-inflammatory cytokine [12]. It binds 
with TLR2 and TLR4 [31], as well as with the receptors 
for advanced glycation end product (RAGE) [23], thus 
inducing an NF-ҡβ signalling pathway [5].
We hypothesised that HMGB1 produced by the 
damaged neurons may play a key role in the neu-
roinflammation and neurodegeneration through ac-
tivation of the NF-ҡβ signalling pathway, specifically 
through RelA (p65). Using an ex-vivo rat optic nerve 
(RON) model, we sought to determine the effects of 
TLR2- and TLR4-bacterial ligands as well as HMGB1, an 
endogenous ligand, on stimulation of NF-ҡβ signalling 
from reactive astrocytes. We also aimed to study their 
neurotoxicity on RON and determine if such effects 
can be blocked by their antagonists. 
MATERIALS AND METHODS
Animals
Wistar male rats weighing 250–300 g were sacri-
ficed following the guidelines for animal handling as 
set out by the Biomedical Ethics Research Committee 
(Reference No. 335 l6). An ex-vivo model of RONs 
was performed as described in previously published 
studies [1, 26]. After dissection, RONs were immedi-
ately washed with an oxygen-bubbled artificial cer-
ebrospinal fluid (aCSF) (126 mM NaCl, 3 mM KCl, 
2 mM MgCl2, 2 mM NaH2PO4, 26 mM NaHCO3, 
10 mM glucose, 2 mM CaCl2·4H2O). Then, each nerve 
was immediately placed onto 6-well tissue culture 
plates (SPL Life Sciences) filled with 5 mL of aCSF 
solution per well. 
Optic nerve treatments with TLR2 and TLR4 
agonists with/without their antagonist
After optic nerve dissection and isolation, the 
RONs were separately treated by 1 µg/mL of lipopol-
ysaccharide (LPS) from Escherichia coli (TLR4 ligand) 
(InvivoGen, catalogue number: 13I06-MM), 10 µg/ 
/mL of zymosan from Saccharomyces cerevisiae (TLR2 
ligand) (InvivoGen, catalogue number: 14L17-MM) or 
1 µg/mL of HMGB1, LPS-free (an endogenous TLR2/4 
ligand) (HMGBiotech, catalogue number: HM-120) 
in a 5 mL well of aCSF media or with aCSF alone as 
a control.
For TLR blocking, nerves were blocked by 10 µg/mL 
of LPS from Rhodobacter sphaeroides (TLR4 antag-
onist) (InvivoGen, catalogue number: 15L17-MM) or 
1 µg/mL of anti-TLR2-monoclonal IgG (TLR2 antago-
nist) (InvivoGen, catalogue number: 10C05-MM) for 
at least 10 min before adding the TLR agonists (LPS, 
zymosan or HMGB1). 
All treated RONs were incubated in an oxygenated 
incubator of 95% O2 and 5% CO2 at 37oC for 60 and 
120 min. Immediately after the experiment, RONs were 
fixed by 4% paraformaldehyde/0.1 M phosphate buffer 
solution (PBS) for 1 h at room temperature and then 
rapidly frozen in Tissue Tec (Sakura) and kept at –80oC.
Immunohistochemistry
Rat optic nerves were sliced by cryostat at 15 µm 
thickness. Then, slides were blocked by 0.1 PBS, 
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10% goat serum and 0.5% Triton (PBST) for 1 h 
at room temperature. Primary antibodies, namely: 
anti-glial fibrillary acidic protein (GFAP) (BioLegend, 
clone number: MCA-5C10) and anti-NF-ҡβ p65 
(BioLegend, clone number: poly6226) were added at 
a concentration of 1:100 for both antibodies and 
kept overnight at 4oC. After several washes with 
PBST, a mix of secondary antibodies (Alexa Fluor 
488-Goat anti-mouse IgG [Abcam, clone number: 
ab150117] and Alexa Fluor 594-Goat anti-rabbit IgG 
[Abcam, clone number: ab150080]) at a concentra-
tion of 1:1000 were added for 2 h. After incubation, 
immunostained slides were washed several times in 
PBST and 0.1 M PBS, and finally placed in mount-
ing media and covered by a coverslip. Images were 
captured using a fluorescence microscope (Olympus 
BX51, Japan), three to five randomly selected area 
on each immunostained slide from RONs (treated 
or un-treated; n = 6) were used for analysis with 
a double-blind producer. 
Image J software was used to calculate the mean 
fluorescence intensity (MFI) of GFAP conjugated to 
Alexa Fluor 488 (green) and NF-ҡβ conjugated to 
Alexa Fluor 594 (red). Co-localisation analysis was 
conducted for both GFAP and NF-ҡβ images using 
Coloc 2 plugins for Image J. The rate of co-expres-
sion was interpreted using the Costes method and 
Pearson’s correlation coefficient.
Dead cell counts
Ethidium bromide is a fluorometric labelling of 
deformation in cell biology that stains the nucleic 
acid of dead cells but is unable to stain the undam-
aged living cells [14, 26]. The sections of RONs, 
which were treated by TLR2 and TLR4 agonists and 
antagonists were stained by ethidium bromide 
(LOBA Chemie, catalogue number: 03715) with 
a dilution of 1:500, were prepared from 10 mg/mL 
stock solution and incubated at room temperature 
for 10 min. Then, these slides were rinsed with PBS 
3 times, mounted and enclosed with a coverslip. 
Images were captured by a fluorescence microscope 
(Olympus BX51, Japan). 
Image J was used blindly to count the number 
of dead cells (NDC) for all nerves. To calculate the 
ratio (%) of dead cells, the NDC of the RONs sections 
treated with LPS, zymosan, HMGB1, LPS with TLR4 
antagonist, zymosan with TLR2 antagonist, HMGB1 
with TLR4 or TLR2 antagonists were divided over the 
NDC of the untreated nerve. 
Statistical analysis 
Graph-Pad Prism software version 7.0 was used to 
analyse the data of MFI for GFAP and NF-ҡβ, as well 
as for the ratio (%) of dead cells. One-way analysis 
of variance (ANOVA; Bonferroni test) was utilised to 
compare the variances between the untreated and 
the treated RONs with different TLR agonists and 
antagonists. P values < 0.05 were considered signif-
icantly different. 
RESULTS 
HMGB1 induces astrocytes reactivity 
We aimed to determine the effects of TLR lig-
ands on the expression levels of GFAP and NF-ҡβ for 
astrocyte reactivity and whether the inflammation 
was specifically co-localised into astrocytes (Fig. 1). 
Immunohistochemical analysis revealed that the rate 
of the co-localisation was higher with LPS (TLR4 ag-
onist, 46%) and did not differ with the zymosan 
(TLR2 agonist, 33%) as compared to the untreated 
RON (33%). Surprisingly, the rate of co-localisation 
was highest after HMGB1 stimulation (91%) and was 
reversed by TLR2 (39%) and TLR4 (41%) antagonists. 
All images demonstrated a significant correlation with 
a Costes test of p value = 1. Moreover, the Pearson’s 
image correlation coefficient was r > 0.5 for all nerves 
treated with TLR ligands. 
HMGB1 augments the inflammation  
via TLR signalling
Although the ratio of co-localisation demonstrat-
ed an astrocytic reaction after TLR ligand treatment, 
we asked if there is a difference between TLR agonists 
and their antagonists. After RON was dissected and 
isolated, the nerves were exposed to LPS, zymosan, 
HMGB1, LPS with TLR4 antagonists, zymosan with 
TLR2 antagonist, HMGB1 either with TLR4 or TLR2 an-
tagonists, or with aCSF alone as an untreated control, 
and they were incubated for 60 or 120 min. Then, the 
immunofluorescence intensities for GFAB and NF-ҡβ 
were measured for untreated and TLR ligand-treated 
nerves, as shown in Figure 2. 
High-mobility group box 1 protein significant-
ly increased expression of both GFAB and NF-kb 
(p = 0.05), like LPS and zymosan (p = 0.01), as com-
pared to the untreated control. Furthermore, this 
augmentation was blocked by both TLR2 and TLR4 an-
tagonists (p = 0.05). These data confirm that HMGB1 
augment the inflammation from astrocytes through 
TLR signalling.
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Figure 2. High-mobility group box 1 protein (HMGB1) induces the expression of inflammation. Representative images of double immunostaining 
by glial fibrillary acidic protein (GFAP; green) and nuclear factor kappa B (NF-ҡB; red) for rat optic nerve (RON) induced by toll-like receptors (TLRs) 
agonist or blocked by TLRs antagonist; A, B. Fluorescence intensity levels of GFAP; C, D. Fluorescence intensity levels of NF-ҡβ, expressed by RONs 
in response to lipopolysaccharides (LPS; TLR4 agonist), zymosan (ZYM) (TLR2 agonist) and HMGB1 with or without TLR2 and TLR4 antagonists, 
either after 60 or 120 min of incubation. Comparisons were assessed between untreated versus treated RON: *p < 0.05; **p < 0.01; or agonist 
versus antagonists: ^p < 0.05, ^^p < 0.01. Values were shown as mean ± SEM. Statistical significance was determined by ANOVA (n = 6).
Figure 1. Co-localisation of reactive astrocytes from rat optic nerve (RON). Representative images of double immunostaining by glial fibrillary 
acidic protein (GFAP; green) and nuclear factor kappa B (NF-ҡB; red) for RON treated with toll-like receptor agonist. Image J was used for 
co-localisation (merge, magenta right panels) analysis and was determined by the Costes method, for which a P value of 1 indicates 100% 
statistical confidence. Pearson’s image correlation coefficient (r) is also represented; LPS — lipopolysacharide; TLR — toll-like receptor; 
HMGB1 — high-mobility group box 1
HMGB1 facilitates neurodegeneration 
We also explored if the nerves were inflamed by 
HMGB1 and if other TLR agonists had some neuro-
degenerative tendency. Particularly, a histology of 
the HMGB1-treated nerve demonstrated extensive 
atrophic and necrotic changes (Fig. 3). Thus, we ex-
amined the number of dead cells after staining with 
ethidium bromide. The ratio of dead cells was signifi-
Treatments Untreated LPS LPS + TLR4 antagonist Zymosan
Zymosan + TLR2 
antagonist HMGB1
HMGB1 + TLR4 
antagonist
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cantly higher with LPS (p = 0.01), zymosan (p = 0.01) 
and HMGB1 (p = 0.05) treatment when compared to 
untreated healthy nerves; after 120 min, but not after 
60 min except for LPS (p = 0.01). Although, the TLR 
antagonists inhibited the LPS- and zymosan-induced 
nerve death, the HMGB1-induced nerve death was 
not reversed by TLR antagonists. 
DISCUSSION 
The presence of HMGB1 is considered to be a risk 
factor for memory impairment, chronic neurodegen-
eration and advanced progression of neuroinflam-
mation [6, 9, 13, 16, 19]. Additionally, the DAMP 
molecule for TLR4 is known to induce sterile neu-
roinflammation [6, 16]. Nevertheless, no study has 
been done to investigate the astroglial inflammatory 
mechanisms resulting from the ligation of HMGB1 
to TLR4 and TLR2 via mediating signalling pathways, 
such as the NF-ҡβ [27]. The results of the current 
study demonstrated that ex-vivo nerves treated with 
HMGB1 have higher expression and co-localisation 
of GFAP and NF-ҡβ as compared to the untreated 
control. Moreover, the HMGB1-induced inflammation 
was inhibited by blocking TLR activity. 
Previously, a Georgia team used different research 
methodologies, including an animal model, human 
CSF and tissue cultures from patients after being 
exposed to traumatic brain injury (TBI), to clarify the 
multifaceted role of HMGB1-TLR4 ligation in pro-
moting neurovascular impairment [15]. They found 
that TLR4 and HMGB1 were highly co-expressed 
post-trauma in a patient’s CSF and exuberated neu-
roinflammatory responses through releasing IL-6 and 
activation of the aquaporin-4, an astrocytic water 
channel [15]. Another study supporting this notion 
demonstrated that elevated levels of HMGB1 in the 
brain induce memory impairment and that this could 
be mediated by TLR4 on a knockout RAGE model [19]. 
Unfortunately, despite their utilisation of animal and 
human tissue cultures, they were not able to identify 
the exact intracellular signalling pathways that lead to 
releasing IL-6 such as NF-ҡβ. Our functional study of 
an ex-vivo model shows that HMGB1 could activate 
astrocytes via TLR4 through NF-ҡβ signalling, support-
ing previous reports that suggest the co-localisation 
and correlation of both TLR4 and HMGB1. 
However, the results of the present study showed 
that the HMGB1-induced cell death was not reversed 
by TLR2 or TLR4 antagonists. There is considerable 
evidence to support the theory that trauma of the 
brain and spinal cord may cause abundant HMGB1 
accumulation [10, 13, 15]. HMGB1, an endogenous 
ligand for TLR4, may cause stimulation of innate im-
munity after trauma [15], but another mechanism, 
such as RAGE, may lead to neuronal damage and 
death [10]. This concept is consistent with a report 
which demonstrated that post-trauma, HMGB1 and 
RAGE are highly co-expressed in both rat and human 
Figure 3. High-mobility group box 1 protein (HMGB1) modulates nerve death and atrophy. Microscopic histological features of rat optic nerves 
(H&E stain) of a healthy untreated nerve and a dead nerve treated with HMGB1 (top panels). Ethidium bromide staining to detect the number 
of dead cells (bottom panels). Graphic representation of the dead cells ratio (%) of lipopolysaccharides (LPS), zymosan (ZYM), HMGB1, LPS 
with TLR4 antagonist, zymosan with TLR2 antagonist, HMGB1 with TLR4/TLR2 antagonist. Comparisons were assessed between untreated 
versus treated rat optic nerve: *p < 0.05, **p < 0.01; or agonist versus antagonists: ^p < 0.05. Values were demonstrated as mean ± SEM. 
Statistical significance was determined ANOVA (n = 6); TLR — toll-like receptor.
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brains [10]. Thus, the accumulated traumatic HMGB1 
could contribute to the pathology of neurodegen-
erative diseases through different mechanism other 
than TLR signalling. 
Furthermore, the NF-ҡβ dimer has diversity in its 
function that could promote neuroprotection, neu-
roinflammation or neurotoxicity [27]. The inhibition of 
NF-ҡβ to astrocytes reduces the chemokine expression 
and leukocyte infiltration into the injured spinal cord 
[8]. Altogether, this means stimulation of NF-ҡβ p65 
through TLR4 will induce inflammation while another 
diversion via RAGE may lead to neuronal degenera-
tion and/or differentiation [30]. Further exploration of 
these signalling pathways will clarify the therapeutic 
approaches that might act to block HMGB1. Actually, 
a recent study reported that HMGB1 inhibition in the 
in-vivo model of TBI showed plummeting of cerebral 
leukocyte recruitments and brain oedema, similar to 
effects of enoxaparin on neurologic recovery [17]. How-
ever, this study has a major limitation in that the sci-
entists did not demonstrate which signalling pathway 
was used by enoxaparin as a target against HMGB1.
CONCLUSIONS
The result of the current study showed that 
HMGB1 activated NF-ҡβ signalling into reactive as-
trocytes, and this was inhibited by TLR4 and TLR2 
antagonists, a result similar to LPS and zymosan lig-
ands of TLR4 and TLR2, respectively. However, further 
work is needed to study the cause of the neuronal 
degeneration resulting from HMGB1. How HMGB1 
modulates neuronal atrophy and death and whether 
this damage is mediated by the RAGE receptor or 
other receptors remain to be determined. Overall, 
HMGB1 is a dangerous molecule for astrocytes that 
will lead to their activation and inflammation and 
subsequent neurotoxicity. Gaining an understand-
ing of these cellular functions may help researchers 
discover therapeutic targets for neurodegenerative 
diseases.
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